Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)
The STAMPEDE2 study is a large research project for men with advanced prostate cancer where the cancer has spread to other parts of the body. These men are already receiving hormone therapy. The study is investigating new ways to treat this type of cancer. Specifically, it's testing a new medication called Pluvicto, given as an injection or infusion, to see if it can improve how long men live and their overall well-being. Researchers will also look at how safe the treatments are, any side effects, and how they affect daily life. The goal is to find better treatments for metastatic hormone-sensitive prostate cancer.
At a glance
What is this study about?
The STAMPEDE2 trial is a really important research study looking into treatments for prostate cancer that has spread and is being treated with hormone therapy. When prostate cancer spreads, it's called 'metastatic', and 'hormone-sensitive' means it still responds to hormone treatments designed to lower male hormones. This study is trying to find the best ways to treat it to help men live longer and feel better.
Researchers will compare existing standard treatments with new approaches, including a specific drug called Pluvicto. This drug is given as an injection or infusion. The main thing they want to find out is if these new treatments help men live for a longer time. They also want to see if the treatments stop the cancer from growing or spreading further, and how they affect a man's quality of life.
By comparing different treatments, the study aims to understand which ones are most effective and safest. This information will help doctors in the future make better decisions about how to treat men with this type of prostate cancer, hopefully leading to improved health and well-being for many patients.
Key takeaways
- The STAMPEDE2 study is researching new treatments for advanced prostate cancer.
- It's for men whose prostate cancer has spread and who are on hormone therapy.
- One new treatment being tested is called Pluvicto.
- The main goal is to see if new treatments help men live longer.
- Researchers will also check for side effects and how treatments affect quality of life.
- Participation involves regular hospital visits, tests, and closely monitoring your health.
Who may be eligible?
This study is looking for men who have prostate cancer that has spread to other parts of the body. This is sometimes called 'metastatic prostate cancer'. You also need to be currently receiving hormone therapy for your prostate cancer.
To be considered for the study, you must be an adult aged 18 years or older. There isn't an upper age limit mentioned, so older men might also be able to take part if they meet the other requirements.
It's important to remember that these are just the basic requirements. A doctor or research nurse involved in the study would need to check many other things about your health and cancer history to see if this particular study is right for you.
- Are you a man aged 18 or older?
- Do you have prostate cancer that has spread?
- Are you currently receiving hormone therapy for your prostate cancer?
- Are you able to attend regular hospital appointments?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join the STAMPEDE2 study, you would be randomly assigned to receive either the standard treatment or one of the new treatments being tested, like Pluvicto. This means you wouldn't get to choose which one you receive. The Pluvicto treatment is given as an injection or infusion.
You would have regular visits to the hospital or clinic. These visits will involve various tests, such as blood tests, scans to check your cancer, and questionnaires about how you're feeling and your quality of life. The research team will monitor you closely for any side effects or changes in your health.
The total duration of your participation would depend on your individual response to treatment and the study's follow-up plan, but it generally involves regular check-ups over an extended period to track the long-term effects of the treatments.
Potential risks and benefits
Locations (3)
- —Ireland
- —Germany
- —Spain
Common questions
What is 'metastatic prostate cancer'?
This means your prostate cancer has spread to other parts of your body, such as your bones or other organs.
What is 'hormone-sensitive' prostate cancer?
This means your cancer is still responding to hormone therapies that lower the amount of male hormones in your body, which helps slow the cancer's growth.
What is Pluvicto?
Pluvicto is the name of one of the new drugs being tested in this study. It's given as an injection or infusion.
How will I know if the treatment is working?
The study team will regularly perform tests, like scans and blood tests, and ask you about your symptoms to monitor how well the treatment is working and how you are feeling.
Will I get to choose which treatment I receive?
No, in this type of study, treatments are assigned randomly, like flipping a coin, to ensure a fair comparison between the different options.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.